IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Inclusion Criteria:
Exclusion criteria:
Clinical.Trials@bms.com855-907-3286
Irvine, California 92612, United States
Orange, California 92868-3201, United States
Mineola, New York 11501, United States
Columbus, Ohio 43210, United States
Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
5411322189001189
ABB, Buenos Aires F.D. C1199ABB, Argentina
Wuhan, Hubei 430030, China
Bogotá, Cundinamarca 111511, Colombia
New Delhi, National Capital Territory of Delhi 110029, India
Ina-machi, Saitama 362-0806, Japan
Nagaizumi-cho,Sunto-gun, Shizuoka 411-8777, Japan
Koto-ku, Tokyo 135-8550, Japan
Florești, Cluj 407280, Romania
Cheongju-si, Chungcheongbuk-do [Chungbuk] 28644, South Korea
Mueng, Changwat Khon Kaen 40002, Thailand
Sulton, Surrey, SM25PT, United Kingdom
970-569-7608
706-660-6449
706-660-6449
312-942-5904
617-632-6049
314-273-8008
775-985-4000
212-731-5662
212-731-5662
631-745-0359
585-922-4020
301-980-8969
614-688-7567
503-215-5696
503-215-5696
267-438-8154
503-494-8426
615-322-4967
434-924-4251
804-828-7999
00543515590424
0000000000
4169464645
8613675007687
+8613802607246
8613212760751
13834563396
0041564862762
41714941111
+88676150011ext.5056
8864235925253218
+886-2353535-3117
88622312345662905
886227372181-3599
886921770588